CG Bio, Seoul Yes Hospital, and Seoul Yes Bio Sign MOU for Cooperation in Advanced Regenerative Medicine

Establishing a Collaborative System for Advanced Regenerative Medicine R&D, Clinical Trials, and Commercialization

CG Bio, a company specializing in bio-regenerative medicine, announced on the 20th that it has signed a three-party memorandum of understanding (MOU) for cooperation in advanced regenerative medicine and healthcare businesses with Seoul Yes Hospital and Seoul Yes Bio.

This agreement represents a strategic partnership among three institutions with distinct areas of expertise: CG Bio, Seoul Yes Hospital?which specializes in spine and joint treatment?and Seoul Yes Bio, a subsidiary of Seoul Yes Hospital responsible for research and development in advanced regenerative medicine. The partnership aims to establish an integrated and organic collaboration system covering the entire cycle of advanced regenerative medicine.

Through the agreement, CG Bio will oversee regulatory and administrative support required for research and development (R&D), product commercialization, and global expansion strategies. It will also serve as the Management Service Organization (MSO) that coordinates planning and operations across the three institutions. Seoul Yes Hospital will be responsible for securing patient groups, providing clinical consultation, and verifying treatment technologies in real-world clinical settings. Seoul Yes Bio will handle basic research, preclinical studies, and clinical development for the creation of therapeutics and medical devices.

The three organizations plan to jointly establish an integrated platform for collaborative research and technology development in advanced regenerative medicine, encompassing the verification and commercialization of treatment technologies. They also intend to pursue joint commercialization through the establishment of a joint venture (JV) in Indonesia, thereby creating a practical business ecosystem that organically connects research and development, clinical trials, and business planning. In addition, the advanced regenerative medicine platform developed through this agreement will be applied to 'NULOOK,' an aesthetic clinic operated by CG Bio in Bali, Indonesia, to serve as a model for the commercialization of advanced regenerative medicine.

Based on this collaborative foundation, the three institutions aim to create an environment in which domestic patients can access high-quality advanced regenerative treatments in Korea without having to rely on expensive overseas medical trips. They also seek to lay the groundwork for the global expansion of K-advanced regenerative medicine.

Yu Hyunseung, CEO of CG Bio, said, "CG Bio is a specialist in bio-regenerative medicine that has commercialized various bio-convergent medical devices. This agreement marks the first step toward becoming a global leader in advanced regenerative medicine, beyond convergent medical devices." He added, "Together with the clinical and R&D capabilities of Seoul Yes Hospital and Seoul Yes Bio, we will build an integrated ecosystem in which technology development, clinical trials, and commercialization are organically connected within a single platform."

This content was produced with the assistance of AI translation services.